赛托生物
(300583)
| 流通市值：26.10亿 | | | 总市值：26.60亿 |
| 流通股本：1.86亿 | | | 总股本：1.90亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 749,188,335.44 | 507,762,685.42 | 259,850,364.44 | 970,601,329.97 |
| 营业收入 | 749,188,335.44 | 507,762,685.42 | 259,850,364.44 | 970,601,329.97 |
| 二、营业总成本 | 796,360,986.67 | 543,997,518.64 | 285,808,740.98 | 1,025,141,490.76 |
| 营业成本 | 655,327,098.98 | 446,758,264.14 | 236,613,828.58 | 784,898,739.68 |
| 税金及附加 | 9,222,608.44 | 6,205,392.39 | 2,807,000.5 | 13,961,207.67 |
| 销售费用 | 9,462,575.93 | 5,742,915.21 | 2,346,104.69 | 15,182,898.36 |
| 管理费用 | 66,563,051.46 | 45,799,367.18 | 22,599,980.39 | 120,474,199.43 |
| 研发费用 | 32,249,551.03 | 22,455,004.72 | 10,449,182.96 | 58,379,409.91 |
| 财务费用 | 23,536,100.83 | 17,036,575 | 10,992,643.86 | 32,245,035.71 |
| 其中:利息费用 | 21,777,304.76 | 15,506,361.01 | 8,771,284.02 | 30,853,015.77 |
| 其中:利息收入 | 1,593,634.73 | 1,233,898.24 | 800,326.73 | 2,407,587.78 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 5,391,355.27 | 4,091,379.24 | 2,770,396.94 | 12,349,077.69 |
| 资产处置收益 | -165,020.44 | -162,577.53 | - | 63,568.85 |
| 资产减值损失(新) | -30,954,604.75 | -23,252,340.73 | -5,679,426.72 | -75,091,679.09 |
| 信用减值损失(新) | -9,637,137.21 | -4,740,822.13 | -2,525,264.58 | 484,583.74 |
| 其他收益 | 8,399,896.25 | 3,314,055.55 | 2,094,882.38 | 14,671,923.73 |
| 四、营业利润 | -74,138,162.11 | -56,985,138.82 | -29,297,788.52 | -102,062,685.87 |
| 加:营业外收入 | 10,613.64 | 9,406.99 | 4,210.01 | 472,365.65 |
| 减:营业外支出 | 1,073,659.07 | 533,322.95 | 460,579.35 | 1,158,551.79 |
| 五、利润总额 | -75,201,207.54 | -57,509,054.78 | -29,754,157.86 | -102,748,872.01 |
| 减:所得税费用 | 3,927,317.08 | 2,327,305.36 | 2,198,782.66 | -1,420,606.43 |
| 六、净利润 | -79,128,524.62 | -59,836,360.14 | -31,952,940.52 | -101,328,265.58 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -79,128,524.62 | -59,836,360.14 | -31,952,940.52 | -101,328,265.58 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -69,230,279.84 | -52,687,137.35 | -27,508,507.98 | -88,766,731.73 |
| 少数股东损益 | -9,898,244.78 | -7,149,222.79 | -4,444,432.54 | -12,561,533.85 |
| 扣除非经常损益后的净利润 | -72,387,914.43 | -53,481,635.07 | -27,813,133.29 | -103,361,225.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.36 | -0.28 | -0.15 | -0.47 |
| (二)稀释每股收益 | -0.36 | -0.28 | -0.15 | -0.47 |
| 九、综合收益总额 | -79,128,524.62 | -59,836,360.14 | -31,952,940.52 | -101,328,265.58 |
| 归属于母公司股东的综合收益总额 | -69,230,279.84 | -52,687,137.35 | -27,508,507.98 | -88,766,731.73 |
| 归属于少数股东的综合收益总额 | -9,898,244.78 | -7,149,222.79 | -4,444,432.54 | -12,561,533.85 |
| 公告日期 | 2025-10-29 | 2025-08-26 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |